Evidence map›Paper›PMID 40017565›Full record

ArticleThe annals of applied statistics2024

INDIVIDUAL DYNAMIC PREDICTION FOR CURE AND SURVIVAL BASED ON LONGITUDINAL BIOMARKERS.

Can Xie, Xuelin Huang, Ruosha Li, Alexander Tsodikov, Kapil Bhalla

Abstract read
In one paragraph

Article in The annals of applied statistics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Can XieDepartment of Biostatistics, The University of Texas MD Anderson Cancer Center.
Xuelin HuangDepartment of Biostatistics, The University of Texas MD Anderson Cancer Center.
Ruosha LiDepartment of Biostatistics and Data Science, The University of Texas Health Science Center at Houston.
Alexander TsodikovDepartment of Biostatistics, University of Michigan.
Kapil BhallaDepartment of Leukemia, The University of Texas MD Anderson Cancer Center.

Funding

University of Texas M.D. Anderson Cancer SPORE-LeukemiaP50CA100632 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI SHPALL, ELIZABETH J · 2003 to 2023
$43.7M
UPR/MDACC Partnership for Excellence in Cancer Research (Luis Segarra supplement)U54CA096300 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI SHARON Hermes GIORDANO · 2002 to 2026
$23.8M
Comparative Modeling of Precision Breast Cancer Control Across the Translational Continuum - SupplementU01CA253911 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI ALAGOZ, OGUZHAN, DE KONING, HARRY J · 2020 to 2025
$10.6M
Modeling Precision Interventions for Prostate Cancer ControlU01CA253915 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI ETZIONI, RUTH D, TSODIKOV, ALEXANDER · 2020 to 2025
$6.5M
Optimizing treatment decision by accounting for longitudinal biomarker trajectories and competing risks of each individualR01CA272806 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Xuelin Huang · 2023 to 2026
$1.5M
Modeling and Validation for Tackling Risk Prediction with Competing Risks by Integrating Multiple Longitudinal BiomarkersR01DK117209 · NIDDK · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI LI, RUOSHA · 2018 to 2021
$1.4M
NCI NIH HHS P50 CA100632NCI NIH HHS R01 CA272806NCI NIH HHS U01 CA253911NCI NIH HHS U01 CA253915NCI NIH HHS U54 CA096300NIDDK NIH HHS R01 DK117209
6 · The paper itself

Abstract

To optimize personalized treatment strategies and extend patients' survival times, it is critical to accurately predict patients' prognoses at all stages, from disease diagnosis to follow-up visits. The longitudinal biomarker measurements during visits are essential for this prediction purpose. Patients' ultimate concerns are cure and survival. However, in many situations, there is no clear biomarker indicator for cure. We propose a comprehensive joint model of longitudinal and survival data and a landmark cure model, incorporating proportions of potentially cured patients. The survival distributions in the joint and landmark models are specified through flexible hazard functions with the proportional hazards as a special case, allowing other patterns such as crossing hazard and survival functions. Formulas are provided for predicting each individual's probabilities of future cure and survival at any time point based on his or her current biomarker history. Simulations show that, with these comprehensive and flexible properties, the proposed cure models outperform standard cure models in terms of predictive performance, measured by the time-dependent area under the curve of receiver operating characteristic, Brier score, and integrated Brier score. The use and advantages of the proposed models are illustrated by their application to a study of patients with chronic myeloid leukemia.

Indexed as

cure modelJoint modelinglinear mixed modellongitudinal biomarkernon-proportional hazard function

Identifiers

PMID40017565
PMCPMC11864788

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.